Abstract
In recent years, great progress has been made in understanding biology and pathogenesis of chronic lymphocytic leukemia. The key thing in disease pathogenesis is the apoptosis resistance of tumor cells. One of the main regulators of programmed cell death is the Bcl-2 family proteins. Important role of Bcl-2 protein in carcinogenesis made it an attractive target for therapeutic intervention. This review focuses on venetoclax (a selective inhibitor of the anti-apoptotic Bcl-2 protein) in the treatment of chronic lymphocytic leukemia.
Highlights
Great progress has been made in understanding biology and pathogenesis of chronic lymphocytic leukemia
This review focuses on venetoclax in the treatment of chronic lymphocytic leukemia
Опубликованы данные исследования, в которое были включены 127 пациентов с рецидивирующим или рефрактерным хроническим лимфоцитарным лейкозом, которым был назначен венетоклакс после прогрессирования на фоне терапии ибрутинибом
Summary
Опубликованы данные исследования, в которое были включены 127 пациентов с рецидивирующим или рефрактерным хроническим лимфоцитарным лейкозом, которым был назначен венетоклакс после прогрессирования на фоне терапии ибрутинибом. Отсутствие МОБ при оценке в периферической крови через 9 мес после окончания комбинированной терапии в рукаве VEN + R было в 62 %, в рукаве RB – в 13 % случаев.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
